- Evgen Pharma, which is focused on the treatment of cancer and neurological conditions, said annual losses narrowed to £3.0m, from £3.6m, on lower operating expenses.

The company recently released encouraging data for a sulforaphane-based treatment for breast cancer.

'"With the ongoing growth of scientific data supporting the therapeutic potential of sulforaphane, together with the positive progress of our Phase II trials, we remain confident in the prospects for the company,' chief executive Stephen Franklin said.

At 2:37pm: [LON:EVG] Evgen Pharma Plc share price was -2.15p at 18.85p

Story provided by